These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 7540143)

  • 41. Structure-activity relationships of neuropeptide Y analogues with respect to Y1 and Y2 receptors.
    Beck-Sickinger AG; Jung G
    Biopolymers; 1995; 37(2):123-42. PubMed ID: 7893945
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Comparison of the solution structures of the chimeric peptides galanin(1-12)-Ala-neuropeptide Y(25-36)amide and galanin(1-12)-Pro-neuropeptide Y(25-36)amide.
    Arvidsson K; Langel U; Ehrenberg A
    Eur J Biochem; 1994 Jun; 222(2):573-81. PubMed ID: 8020494
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Conformational and biological studies of neuropeptide Y analogs containing structural alterations.
    Fournier A; Gagnon D; Quirion R; Cadieux A; Dumont Y; Pheng LH; St-Pierre S
    Mol Pharmacol; 1994 Jan; 45(1):93-101. PubMed ID: 8302286
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Vasoconstrictor effects of various neuropeptide Y analogues on the rat tail artery in the presence of phenylephrine.
    Tschöpl M; Miller RC; Pelton J; Stoclet JC; Bucher B
    Br J Pharmacol; 1993 Nov; 110(3):1098-104. PubMed ID: 8298798
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Characterization of the alpha1-adrenergic chronotropic response in neuropeptide Y-treated cardiomyocytes.
    Sun LS; Rybin VO; Steinberg SF; Robinson RB
    Eur J Pharmacol; 1998 May; 349(2-3):377-81. PubMed ID: 9671120
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Stabilization of alpha-helix in C-terminal fragments of neuropeptide Y.
    Yumoto N; Murase S; Hattori T; Yamamoto H; Tatsu Y; Yoshikawa S
    Biochem Biophys Res Commun; 1993 Nov; 196(3):1490-5. PubMed ID: 8250906
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Further studies on the structural requirements for polypeptide-mediated histamine release from rat mast cells.
    Jasani B; Kreil G; Mackler BF; Stanworth DR
    Biochem J; 1979 Sep; 181(3):623-32. PubMed ID: 92986
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Structure-activity analysis of N-acetyl [Leu(28,31)] NPY 24-36: a potent neuropeptide Y Y(2) receptor agonist.
    Smith-White MA; Potter EK
    Neuropeptides; 1999 Dec; 33(6):526-33. PubMed ID: 10657536
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Neuropeptide Y promotes GTP photo-incorporation into a 55 kDa protein.
    Zhu J; Toews ML; MacDonald RG; Hexum TD
    Eur J Pharmacol; 1994 Aug; 268(3):279-91. PubMed ID: 7805755
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A novel neuropeptide Y analog, N-acetyl [Leu28,Leu31]neuropeptide Y-(24-36), with functional specificity for the presynaptic (Y2) receptor.
    Potter EK; Barden JA; McCloskey MJ; Selbie LA; Tseng A; Herzog H; Shine J
    Eur J Pharmacol; 1994 May; 267(3):253-62. PubMed ID: 8088364
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The contribution of helical potential to the in vitro receptor binding activity of a neuropeptide Y N-terminal deletion fragment.
    Doughty MB; Hu L
    Biopolymers; 1993 Aug; 33(8):1195-206. PubMed ID: 8364154
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Immunologically induced histamine release from rat peritoneal mast cells is enhanced by low levels of substance P.
    Lau AH; Chow SS; Ng YS
    Eur J Pharmacol; 2001 Mar; 414(2-3):295-303. PubMed ID: 11239931
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Neuropeptide Y inhibits alpha-MSH release from rat hypothalamic slices through a pertussis toxin-sensitive G protein.
    Blasquez C; Jégou S; Tranchand Bunel D; Fournier A; Vaudry H
    Brain Res; 1992 Nov; 596(1-2):163-8. PubMed ID: 1334775
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Rapid degradation of neurotensin by stimulated rat mast cells.
    Cochrane DE; Carraway RE; Boucher W; Feldberg RS
    Peptides; 1991; 12(6):1187-94. PubMed ID: 1726119
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Neuropeptide Y, a putative cotransmitter in noradrenergic neurons, induces mast cell degranulation but not prostaglandin D2 release.
    Arzubiaga C; Morrow J; Roberts LJ; Biaggioni I
    J Allergy Clin Immunol; 1991 Jan; 87(1 Pt 1):88-93. PubMed ID: 1825102
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Neuropeptide Y and neuropeptide Y18-36. Structural and biological characterization.
    Boublik J; Scott N; Taulane J; Goodman M; Brown M; Rivier J
    Int J Pept Protein Res; 1989 Jan; 33(1):11-5. PubMed ID: 2722395
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Characterization of neuropeptide-induced histamine release from human dispersed skin mast cells.
    Lowman MA; Benyon RC; Church MK
    Br J Pharmacol; 1988 Sep; 95(1):121-30. PubMed ID: 2464382
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Conformational analysis of neuropeptide Y segments by CD, NMR spectroscopy and restrained molecular dynamics.
    Gurrath M; Bisello A; Bottazzo K; Chung CW; Mammi S; Peggion E
    J Pept Sci; 1996; 2(3):176-93. PubMed ID: 9231326
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Bioactivities and secondary structure of mast cell degranulating (MCD) peptide analogs.
    Buku A; Maulik G; Hook WA
    Peptides; 1998; 19(1):1-5. PubMed ID: 9437730
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Structure and dynamics of micelle-bound neuropeptide Y: comparison with unligated NPY and implications for receptor selection.
    Bader R; Bettio A; Beck-Sickinger AG; Zerbe O
    J Mol Biol; 2001 Jan; 305(2):307-29. PubMed ID: 11124908
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.